<DOC>
	<DOCNO>NCT01270009</DOCNO>
	<brief_summary>MM account 10 % hematopoietic malignancy . Despite use various drug combination chemotherapy , life expectancy MM patient exceed 7 year . Until , lack specific marker disease allow efficient specific molecular targeting . In view preliminary result , antiapoptotic protein Bcl-B could novel diagnostic pronostic marker MM . Therefore , main objective confirm Bcl-B indeed novel diagnostic pronostic marker new potential therapeutic target MM . Targeting Bcl-2 family member 's promising strategy treatment hematopoietic malignancy . In context , specific target Bcl-B could improve treatment patient suffer MM . Of note , could achieve convert antiapoptotic function Bcl-B proapoptotic one thanks use small mimetic peptide derive Nur77 one interactors .</brief_summary>
	<brief_title>Role BCL-B Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patients Multiple Myeloma MGUS newly diagnose Service de Medecine InterneCancerologie department Nice CHU</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>